Claims

1. Compound mixture, comprising 4-[(S)-2-Azetidin-l-yl-l-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide, or physiologically acceptable salts thereof, and an inhibitor of Her2, or physiologically acceptable salts thereof.

2. Compound mixture according to Claim 1, wherein the Her2 inhibitor is trastuzumab or lapatinib.

3. Pharmaceutical composition, comprising a compound mixture according to any of Claims 1 or Claim 2.

4. Pharmaceutical composition according to Claim 3, further comprising excipients and/or adjuvants.

5. Set (kit) consisting of separate packs of

(a) an effective amount of 4-[(S)-2-Azetidin-l-yl-l-(4-chloro-3-trifluoromethylphenyl) -ethylamino]-quinazoline-8-carboxylic acid amide or physiologically acceptable salts thereof; and

(b) an effective amount of a Her2 inhibitor, or physiologically acceptable salts thereof.

6. 4-[(S)-2-Azetidin--l-yl-l-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide, or physiologically acceptable salts thereof, and a Her2 inhibitor, or physiologically acceptable salts thereof for use in the prophylaxis or treatment of cancer.

7. The use of 4-[(S)-2-Azetidin-l-yl-l-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]quinazoline-8-carboxylic acid amide, or physiologically acceptable salts thereof, and a Her2 inhibitor, or physiologically acceptable salts thereof in the manufacture of a medicament for the prophylaxis or treatment of human breast cancer.

8. The use according to Claim 7, wherein the 4-[(S)-2-Azetidin-l-yl-l-(4-chloro-3-trifluoromethyl-phenyl)ethylamino]-quinazoline-8-carboxylic acid amide and the Her2 inhibitor are to be administered simultaneously.

9. The use according to Claim 7, wherein the 4-[(S)-2-Azetidin-l-yl-l-(4-chloro-3-trifluoromethyl-phenyl)ethylamino]quina-zoline-8-carboxylic acid amide and the Her2 inhibitor are to be administered sequentially.

10. The use according to Claim 7, wherein the Her2 inhibitor is to be administered first.